Healthcare
•3753 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3753)
| Company | Market Cap | Price |
|---|---|---|
|
BBUC
Brookfield Business Corporation
Operates private hospitals and related hospital services.
|
$2.65B |
$36.46
-0.46%
|
|
DNLI
Denali Therapeutics Inc.
DNL310 and DNL126 are recombinant enzymes delivered via Denali's TransportVehicle platform, representing its core product categories.
|
$2.63B |
$17.98
-4.26%
|
|
ATEC
Alphatec Holdings, Inc.
Alphatec's primary business is spine/orthopedic implants and devices.
|
$2.63B |
$17.75
+1.69%
|
|
BHC
Bausch Health Companies Inc.
Xifaxan and the RED-C program are oral small-molecule therapeutics within the Salix hepatology portfolio.
|
$2.58B |
$6.99
-3.79%
|
|
TXG
10x Genomics, Inc.
TXG directly manufactures and sells diagnostic instrument platforms for single-cell and spatial biology workflows.
|
$2.55B |
$20.51
-3.25%
|
|
APLS
Apellis Pharmaceuticals, Inc.
SYFOVRE is an ophthalmic drug (intravitreal) approved for geographic atrophy, representing a direct product Apellis sells.
|
$2.52B |
$19.94
-2.87%
|
|
TWST
Twist Bioscience Corporation
Twist's antibody libraries for drug discovery align with the Antibody Discovery Platform investable theme.
|
$2.50B |
$41.44
+0.41%
|
|
GEO
The GEO Group, Inc.
Provides continuum of care rehabilitation and post-release services as part of corrections/rehabilitation programs.
|
$2.49B |
$17.64
+0.83%
|
|
TVTX
Travere Therapeutics, Inc.
Lead product FILSPARI (sparsentan) is an oral small molecule therapeutic for IgA nephropathy, representing the core commercial and product-focused program.
|
$2.48B |
$27.87
-1.87%
|
|
ALMS
Alumis Inc. Common Stock
Alumis is developing oral TYK2 inhibitors (ESK-001 and A-005), a major product category of oral small molecule therapeutics.
|
$2.48B |
$23.86
-1.30%
|
|
IRON
Disc Medicine, Inc.
Disc Medicine concentrates on rare hematologic diseases (e.g., EPP, Diamond-Blackfan anemia) by targeting iron and heme pathways, with a pipeline centered on rare-disease indications.
|
$2.47B |
$71.00
-0.06%
|
|
DYN
Dyne Therapeutics, Inc.
Dyne's FORCE platform is a drug delivery platform enabling targeted payload delivery to muscle and CNS, making it a core product category.
|
$2.38B |
$16.70
+1.74%
|
|
AAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
Ascentage Pharma is a biotech company focused on oncology, developing apoptosis-targeted cancer therapies (olverembatinib, lisaftoclax, alrizomadlin).
|
$2.36B |
$27.08
-0.81%
|
|
SPNT
SiriusPoint Ltd.
Accident & Health lines indicate health-related insurance offerings, aligned with Health Insurance.
|
$2.34B |
$19.99
-2.01%
|
|
OMCL
Omnicell, Inc.
XT Series automated dispensing systems, XR2 robot, IVX compounding robot are medical devices and biometrics products.
|
$2.32B |
$50.53
-0.88%
|
|
RCUS
Arcus Biosciences, Inc.
Arcus operates in oncology with innovative IO therapies (HIF-2α inhibitor casdatifan; TIGIT antibody domvanalimab; CD73 inhibitor quemliclustat) making it a Biotech - Oncology company.
|
$2.32B |
$21.80
+0.02%
|
|
OGN
Organon & Co.
Directly manufactures/markets medical devices (Nexplanon implant and Jada System) used in women's health and obstetric care.
|
$2.28B |
$8.75
+0.57%
|
|
BBAI
BigBear.ai Holdings, Inc.
VeriScan biometric traveler processing indicates biometrics/biometric sensing offerings.
|
$2.27B |
$6.12
-0.81%
|
|
SLNO
Soleno Therapeutics, Inc.
Core product category: Soleno's VYKAT XR is an oral small molecule therapeutic (diazoxide choline extended-release) targeting hyperphagia in Prader-Willi Syndrome.
|
$2.26B |
$42.52
+1.35%
|
|
QDEL
QuidelOrtho Corporation
QuidelOrtho directly develops diagnostic instruments and platforms (including molecular diagnostics platforms) used in labs, aligning with Diagnostic Equipment.
|
$2.25B |
$33.19
-6.19%
|
|
XRAY
DENTSPLY SIRONA Inc.
XRAY directly manufactures dental equipment used in clinical practice (imaging, CAD/CAM, etc.), fitting this tag.
|
$2.24B |
$11.29
+0.13%
|
|
EYE
National Vision Holdings, Inc.
Provides eye care services including eye exams across its store network.
|
$2.22B |
$28.02
-4.81%
|
|
GLPG
Galapagos N.V.
Core product category: CAR-T and other cell therapies (cell therapy platform).
|
$2.21B |
$33.52
-1.50%
|
|
WVE
Wave Life Sciences Ltd.
Wave Life Sciences' core products are stereopure oligonucleotides and oligonucleotide therapeutics (antisense/siRNA/editing AIMers) used as RNA medicines.
|
$2.17B |
$13.65
-2.95%
|
|
MLYS
Mineralys Therapeutics, Inc.
The company is pursuing a cardiovascular hypertension therapy, placing Mineralys under the Cardiovascular Drugs category.
|
$2.17B |
$32.75
+4.37%
|
|
RARE
Ultragenyx Pharmaceutical Inc.
Ultragenyx is a rare-disease focused biotech company with approved therapies and a pipeline centered on ultra-rare diseases.
|
$2.17B |
$22.50
-4.26%
|
|
ETNB
89bio, Inc.
Pegozafermin is a peptide-based therapeutic; directly marketed as a Peptide Therapeutics product.
|
$2.17B |
$14.85
+0.07%
|
|
NHC
National HealthCare Corporation
NHC operates integrated healthcare services and facilities, including skilled nursing, home health, hospice, and behavioral health services.
|
$2.13B |
$137.30
-1.23%
|
|
KN
Knowles Corporation
Knowles has a significant MedTech / medical device presence via advanced microphones and related audio components used in medical devices.
|
$2.11B |
$24.57
-1.44%
|
|
PGNY
Progyny, Inc.
Progyny Rx is an integrated pharmacy benefits solution, aligning with PBM-like capabilities for medications within its program.
|
$2.11B |
$24.52
+0.88%
|
|
AVDL
Avadel Pharmaceuticals plc
LUMRYZ is an oral small molecule therapeutic (sodium oxybate) used to treat narcolepsy; Avadel's core product.
|
$2.09B |
$21.50
+0.07%
|
|
HRMY
Harmony Biosciences Holdings, Inc.
Harmony's WAKIX and pipeline assets target rare neurological diseases, aligning with Biotech - Rare Diseases.
|
$2.08B |
$36.18
-0.63%
|
|
PRGO
Perrigo Company plc
Digestive Health OTC products are a significant Perrigo self-care category.
|
$2.07B |
$15.02
-1.02%
|
Showing page 10 of 38 (3753 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
